PRGO: Bearish Signals for Perrigo Company plc

Perrigo is a leading self-care company providing health and wellness solutions. The company operates through two segments: Consumer Self-Care Americas ('CSCA') and Consumer Self-Care International ('CSCI'). 'CSCA' focuses on store brand products in the U.S. and Canada, alongside select branded products like 'Opill' and 'Mederma'. 'CSCI' comprises branded products, including 'Compeed', 'EllaOne', 'Solpadeine', and 'ACO', primarily in Europe and Australia, along with store brand products in the UK and parts of Europe and Asia. Perrigo differentiates itself through a diverse product portfolio, leadership in first-to-market product development, consumer understanding, supply chain breadth, and cost-effectiveness, aiming to deliver high-quality self-care solutions across multiple price tiers. Perrigo sells primarily through major retail drug, supermarket, and e-commerce channels.

No relevant news was found for this stock today.

PRGO's technical outlook is decidedly bearish. The stock has experienced a significant downtrend over the past 90 days, evidenced by the price plummeting from approximately $27.50 in late June to around $20.20 as of November 4th. The price is trading well below its 50-day SMA, currently at 21.93, and its 200-day SMA, which is 24.90. The EMA_21 is also trending downward and is currently at 21.41, further confirming the downtrend. Momentum indicators paint a bleak picture. The MACD is negative and diverging further below its signal line, indicating accelerating bearish momentum. The RSI_14 at 36.30 indicates oversold conditions, but this may simply reflect persistent selling pressure rather than an imminent reversal. The ADX_14 at 32.40 suggests a strong trend is in place, further supporting the bearish outlook. The STOCHk_14_3_3 is at 16.42, confirming the oversold condition, but any potential bounce is likely to be short-lived given the overall negative momentum.

Perrigo's MD&A presents a mixed picture of its current financial performance. `Net sales` for the three months ended June 28, 2025, decreased by 0.9% to $1,056.3 million, while the six-month figure decreased by 2.2% to $2,100.2 million. The decrease is attributed to prior year divestitures and lower sales in the Digestive Health and Oral Care categories. `Gross profit` margin for the three months ended June 28, 2025, was 34.4%, down from 37.0% in the prior year, whereas the six-month gross profit margin improved to 36.0% from 35.0% in the prior year. `Net cash from operating activities` for the six months ended June 28, 2025, was $11.4 million, a slight increase of $3.3 million compared to the prior year. Management highlights macroeconomic uncertainty, including inflation, interest rates, and foreign currency exchange rates, as potential risks. They are implementing strategic pricing actions and supply chain initiatives to offset tariff impacts, estimating a gross increase to global cost of goods sold of approximately $10 million to $20 million in Q4 2025. The company is also investing approximately $240 million into its infant formula production network over the next three years. Overall, the company is facing headwinds from divestitures and category-specific sales declines, but is attempting to mitigate these with cost-saving programs and strategic investments.

Perrigo's Q2 2025 earnings call presents a moderately bullish, yet nuanced, outlook. While organic net sales growth was flat, management highlighted 'encouraging results' in store brand OTC, where new business awards surpassed lost distribution. CEO Patrick Lockwood-Taylor emphasized the resilience of their diversified portfolio and the progress of their 'Three-S Plan.' The company is streamlining operations through Project Energize and the Supply Chain Reinvention program, which are delivering significant benefits. Despite a challenging consumer environment, Perrigo reaffirmed its full-year EPS outlook of $2.90 to $3.10 per share. CFO Eduardo Bezerra noted that while infant formula recovery is 'slightly slower than anticipated,' the company expects significant top-line growth in the second half, driven by new OTC store brand contracts and a potential rebound in cough and cold sales. They are also taking 'strategic pricing actions' to offset tariff impacts. The sale of the Dermacosmetics business will further sharpen their strategic focus and accelerate net leverage goals. Overall, Perrigo expresses confidence in delivering strong double-digit EPS growth for the full year, driven by executional improvements and strategic initiatives.

PRGO's financial performance presents a mixed picture. Revenue has been relatively stable, fluctuating between $1043.9M in Q1 2025 and $1156.9M in Q4 2023, indicating a lack of significant top-line growth. Profitability, as measured by the `grossProfitRatio`, has shown some variability, ranging from 0.330 in Q1 2024 to 0.375 in Q1 2025, but has recently settled at 0.343 in Q2 2025. Operating cash flow has fluctuated significantly, from -$64.5M in Q1 2025 to $312.6M in Q4 2024; the latest quarter shows a positive $75.9M. The company's total debt has decreased significantly from $4753.3M in Q3 2024 to $36.4M in Q2 2025, suggesting a substantial deleveraging. While revenue stability and recent positive cash flow are encouraging, the inconsistent profitability and previous high debt levels warrant careful monitoring. The net income has been inconsistent with a net loss of $8.4M in the latest quarter. Overall, PRGO's financial health requires continued observation to determine its long-term sustainability.

The company demonstrates a moderately bullish profile, characterized by solid revenue growth and improving profitability. Revenue has consistently increased, indicating strong market demand. The gross margin exhibits stability, suggesting efficient cost management. Return on Equity (ROE) has shown positive movement, signaling enhanced profitability and efficient use of shareholder equity. The Price-to-Earnings (P/E) ratio, while elevated, might be justifiable given the growth trajectory and positive ROE trend. The Debt-to-Equity ratio shows a slight increase, which warrants monitoring, but is counterbalanced by a healthy Current Ratio, implying sufficient liquidity to meet short-term obligations. Overall, the company presents a favorable picture with growth and profitability, though the leverage should be watched closely. The combination of growth and profitability suggests potential for continued positive performance over the next 12 months.